Allergan reported a net loss attributable to ordinary shareholders of $4.3 billion, or $12.83 per basic share, in the fourth quarter of 2018 compared with a net income of $3 billion, or $9.21 per basic share, in the same quarter of 2017, according to a press release.
For the full year, Allergan reported a net loss attributable to ordinary shareholders of $5.1 billion, or $15.26 per basic share, compared with a net loss of $4.4 billion, or $13.19 per basic share, in 2017.
Net revenues totaled nearly $4.1 billion in (Read more...)
Uncategorized